Seeing Is Believing
Currently out of the existing stock ratings of Andrew Baum, 23 are a HOLD (33.33%), 44 are a BUY (63.77%), 2 are a SELL (2.9%).
Analyst Andrew Baum, currently employed at CITI, carries an average stock price target met ratio of 59.42% that have a potential upside of 19.29% achieved within 369 days.
Andrew Baum’s has documented 142 price targets and ratings displayed on 11 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on BMY, Bristol-Myers Squibb Company at 12-Nov-2024.
Analyst best performing recommendations are on ALVO (ALVOTECH).
The best stock recommendation documented was for BMY (BRISTOL-MYERS SQUIBB COMPANY) at 10/25/2024. The price target of $55 was fulfilled within 6 days with a profit of $3.08 (5.93%) receiving and performance score of 9.89.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$206
$30.34 (17.27%)
$153
16 days ago
(22-Nov-2024)
13/14 (92.86%)
$27.92 (15.68%)
293
Buy
$205
$29.34 (16.70%)
23 days ago
(15-Nov-2024)
2/3 (66.67%)
$39.27 (23.70%)
507
Buy
$200
$24.34 (13.86%)
$190
25 days ago
(13-Nov-2024)
12/13 (92.31%)
$28.57 (16.67%)
490
Buy
$224
$48.34 (27.52%)
$231
26 days ago
(12-Nov-2024)
12/15 (80%)
$48.86 (27.90%)
488
Buy
$215
$39.34 (22.40%)
$226
26 days ago
(12-Nov-2024)
8/10 (80%)
$39.86 (22.76%)
293
Which stock is Andrew Baum is most bullish on?
Which stock is Andrew Baum is most reserved on?
What Year was the first public recommendation made by Andrew Baum?